Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

Off-target effects of systemically administered drugs have been a major hurdle in designing
therapies with desired efficacy and acceptable toxicity. Developing targeting strategies to …

Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables
the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full …

Antibody–Drug Conjugates (ADCs) are now established as a major class of therapeutics for
the clinical treatment of cancer. The properties of the linker between the antibody and the …

Simple Summary Antibody-drug conjugates (ADC) are a rapidly expanding class of anti-
cancer drugs, with twelve agents in current clinical use. Despite recent successes, many …

Antibody–drug conjugates (ADCs) are a family of targeted therapeutic agents for the
treatment of cancer. ADC development is a rapidly expanding field of research, with over 80 …

Breast tumors generally consist of a diverse population of cells with varying gene expression
profiles. Breast tumor heterogeneity is a major factor contributing to drug resistance …

The primary purpose of ADCs is to increase the efficacy of anticancer medications by
minimizing systemic drug distribution and targeting specific cells. Antibody conjugates …

Antibody-drug conjugates (ADCs) are a class of innovative biopharmaceutical drugs, which,
via their antibody (mAb) component, deliver and release their potent warhead (aka. payload) …

Abstract Antibody Drug Conjugate (ADC) is an emerging technology to overcome the
limitations of chemotherapy by selectively targeting the cancer cells. ADC binds with an …